The VHL (von Hippel-Lindau) tumour-suppressor protein forms a multi-protein complex [VCB (pVHL-elongin C-elongin B)-Cul-2 (Cullin-2)] with elongin C, elongin B, Cul-2 and Rbx1, acting as a ubiquitin-ligase (E3) and directing proteasome-dependent degradation of targeted proteins. The α-subunit of Hif1α (hypoxia-inducible factor 1α) is the principal substrate for the VCB-Cul-2 complex; however, other substrates such as aPKC (atypical protein kinase C) have been reported. In the present study, we show with FRET (fluorescence resonance energy transfer) analysis measured by FLIM (fluorescence lifetime imaging microscopy) that PKCδ and pVHL (VHL protein) interact directly in cells. This occurs through the catalytic domain of PKCδ (residues 432-508), which appears to interact with two regions of pVHL, residues 113-122 and 130-154. Despite this robust interaction, analysis of the PMA-induced proteasome-dependent degradation of PKCδ in different RCC (renal cell carcinoma) lines (RCC4, UMRC2 and 786 O) shows that there is no correlation between the degradation of PKCδ and the presence of active pVHL. Thus, in contrast with aPKC, PKCδ is not a conventional substrate of the ubiquitin-ligase complex, VCB-Cul-2, and the observed interaction between these two proteins must underlie a distinct signalling output.
INTRODUCTION
The VHL (von Hippel-Lindau) tumour-suppressor gene is responsible for inherited familial VHL cancer syndrome, and mutations of the VHL gene, accompanied by loss of heterozygosity, are also found in 70-80 % of sporadic clear cell RCCs (renal cell carcinomas) and haemangioblastomas [1] . pVHL (VHL protein) has been shown to associate with elongin C, elongin B, Cul-2 (Cullin-2) and the ring finger protein, Rbx1, to form the VCB (pVHL-elongin C-elongin B)-Cul-2 complex. pVHL has been extensively studied, and its most well understood function to date is as a ubiquitin-ligase (E3) specific for Hif1α (hypoxia-inducible factor-1α), the regulatory subunit of the transcription factor Hif1 (for a review, see [2] ). During normoxia, Hif1α is degraded via the ubiquitin-proteasome pathway by an oxygen-dependent mechanism controlled by proline hydroxylases [3] [4] [5] . As a consequence of inactivation of the VHL gene, Hif1α expression is stabilized and the expression level of VEGF (vascular endothelial growth factor) is increased with subsequent stimulation of angiogenesis. Whereas Hif1α is the best characterized substrate of pVHL, it is predicted that it is the spectrum of such substrates which underlies the distinctive clinical phenotypes associated with specific VHL mutations.
PKC (protein kinase C) δ belongs to a superfamily of lipidactivated serine/threonine kinases, comprising at least ten different proteins involved in a diverse range of intracellular functions. PKCs are divided into three distinct subfamilies (classical, novel and atypical) based on their mechanism of activation, PKCδ belongs to the novel subfamily (for a review, see [6] ). Activation of classical and novel PKC isoforms induced by the phorbol ester class of tumour promoters (such as PMA), typically leads to their activation and eventual down-regulation; the complex effects of these agents being defined in part by this acute-gainand chronic-loss-of-function response. This down-regulation of the activity of PKCs, has been reported to be mediated by a ubiquitin-proteasome-dependent pathway(s); ubiquitination and degradation of PKCα, δ and ε have been described in rat 3Y1 cells upon chronic activation by phorbol esters [7] . Similarly, ubiquitination of activated PKCζ in HeLa cells [8] and of activated PKCη in baby hamster kidney cells [9] has been observed. More recently, we have shown that PMA-and cellcycle-induced degradation of PKCδ in NIH3T3 cells is mediated by polyubiquitination of the protein and is dependent on phosphorylation of the activation loop of PKCδ (Thr 505 ) [10] . PKC isoforms, in particular PKCδ and PKCζ , have been shown to bind pVHL and also to up-regulate VEGF expression by activating MAPK (mitogen-activated protein kinase) in cells that lack pVHL activity [11] . pVHL has been shown to ubiquitinate PKC λ/ι, and is to date the only ubiquitin-ligase described that shows specificity for a member of the PKC family [12] . With respect to PKCδ, evidence has previously been presented indicating that pVHL is able to inhibit IGF-I (insulin-like growth factor-I)-mediated cell signalling by directly blocking the association of PKCδ with the IGF-IR (IGF-I receptor) [13] . Moreover, PKCδ has been shown to be activated upon hypoxia and to relay hypoxic signals to Hif1 and heat-shock transcription factor in endothelial cells [14] .
The responses described above provide evidence that PKCδ has a relationship with pVHL, and this is of potential importance in that it may be informative of the phenotypic diversity of pVHL mutations. However, whether pVHL exerts its action towards PKCδ via its ubiquitin-ligase function and/or, as alluded to above, a modulatory function towards this protein kinase remains unresolved. In order to probe the pVHL/PKCδ relationship, we have demonstrated the interaction of these proteins in intact cells by employing FRET (fluorescence resonance energy transfer) analysis. We have further mapped this interaction to the CD (catalytic domain) of PKCδ and have extended these studies to determine the pattern of interactions for a series of pVHL mutations found in human tumours. The evidence indicates that PKCδ interacts with pVHL via two regions of pVHL. Interactions display a characteristic pattern of behaviour indicative of a role in pVHL mutant-specific phenotypes. To determine whether this pattern of interaction correlates with activation-induced PKCδ downregulation, we have investigated a series of RCCs that express either WT (wild-type) or mutant pVHL. The results show that pVHL does not directly promote the degradation of PKCδ nor does it inhibit catalytic activity in cells, indicating that distinctive signalling role(s) for the cellular complex characterize this interaction.
EXPERIMENTAL Antibodies
Anti-PKCδ specific antibodies were purchased from Santa Cruz (rabbit polyclonal C-20). Antibodies against PKCε and actin were obtained from Santa Cruz (rabbit anti-PKCε C-20; goat antiactin). Anti-Hif1α and anti-PKCι-specific antibodies were from BD Transduction Laboratories (mouse monoclonal antibodies). A rabbit anti-PKCζ N-terminal antibody was generously provided by Dr T. Sacktor (Department of Physiology and Pharmacology, State University of New York Downstate Medical Center, Brooklyn, New York, NY, U.S.A.). A mouse anti-(α tubulin) antibody was purchased from Sigma-Aldrich. Polyclonal antisera to the Ser 299 phosphorylation site in PKCδ were raised in rabbits (J. Durgan and P. J. Parker, unpublished work).
Cell culture and treatments
RCC4, UMRC2 and 786 O cell lines were maintained in DMEM (Dulbeco's modified Eagle's medium) containing 10 % (v/v) FBS (foetal bovine serum), 50 units/ml penicillin/50 µg/ml streptomycin and 0.5 mg/ml G418. COS7 and HEK-293T [where T stands for large T-antigen of SV40 (simian virus 40)] cells were maintained in DMEM containing 10 % (v/v) FBS, 50 units/ ml penicillin/50 µg/ml streptomycin. All the cells were cultured at 37
• C, 5 % CO2. COS7 and HEK-293T cells were transfected with Lipofectamine TM 2000 (Invitrogen) according to the manufacturer's instructions.
For the steady-state experiments, the RCC4 line [VA (vector alone) and VHL] were seeded at 25 % and 100 % confluency and maintained for 48 h before harvesting of the cells in sample buffer [100 mM Tris/HCl (pH 6.8), 4 % (w/v) SDS and 20 % (w/v) glycerol]. The amount of protein was determined by bicinchoninic acid assay (Pierce) and protein levels were adjusted to 0.1 µg/µl by diluting the sample with water, DTT (dithiothreitol; 1M) and Bromophenol Blue.
For all the drug treatment experiments RCC4, UMRC2 and 786 O cells (VA and VHL) were seeded at 100 % confluency, maintained for 24 h to recover, and starved overnight in DMEM containing 0.5 % FBS. The cells were then treated with 400 nM PMA (Sigma) for various times before harvesting of all samples in SB2× (sample buffer 2×). For the treatments with drugs such as the protease inhibitor, MG132 (25 µM), calyculin A (10 µM), BIM-I (bisindolylmaleimide I; 10 µM), the PKC inhibitors Gö 6976 (1 µM) and rotterlin (5 µM) (Calbiochem), RCC4 lines were pre-treated for 30 min prior to stimulation with PMA and were harvested as described above. Cell extracts were resolved by SDS/PAGE and proteins were analysed by Western-blot analysis using specific antibodies.
Plasmid constructs
The VHL ORF (open reading frame) was introduced into pEYFP (enhanced yellow fluorescent protein)-C1 or pEGFP (enhanced green fluorescent protein)-N1 (BD Clontech). pVHL-WT-YFP and pVHL-WT-GFP constructs were made by amplifying the VHL ORF by PCR, using the flanking primers, A, 5 -cggaattctatgccccggagggcggagaac-3 (EcoRI site); B, 5 -gcgggatcctcaatctcccatccgttgatgt-3 (BamHI site), and C, 5 -cggaattctcataatgccccggagggcggagaac-3 (EcoRI site); D, 5 -ccgggatccgcatctcccatccgttgatgtgc-3 (BamHI site) respectively. pVHL truncations and deletions were generated using the forward primer, C, described above (pVHL-WT-GFP) and the following primers: pVHL122-GFP, 5 -gcgggatccgcatctctgaagagccaaaggtg-3 (BamHI site); pVHL113-GFP, 5 -gcgggatccgctcggtagctgtggatgcggcgcg-3 (BamHI site).
For the pVHL 87-130-GFP construct, pVHL 87-130-T7-T7-His 6 -pVHL 87-130 was used as the PCR template with the pVHL-WT-GFP flanking primers, C and D. For pVHL point mutations, site-directed mutagenesis was carried out with two PCR steps. The forward primer, 5 -catgaccttatgggactttcctac-3 and the reverse primer, 5 -gctgttgtagttgtactccagc-3 were used with the following specific complementary primers for each mutation (the underlined bases encode the new amino acid residue): pVHL-Y98H-GFP, 5 -ggcgagccgcagccccacccaacgctgccgcctgg-3 and 5 -ccaggcggcagcgttgggtggggctgcggctcgcc-3 ; pVHL-C162W-GFP, 5 ctctgaaagagcgatggctccaggttgtccg-3 and 5 -cggacaacctggagccatcgctctttcagag-3 ; pVHL-R167W-GFP, 5 -gcctccaggttgtctggagcctagtcaagcctg-3 and 5 -caggcttgactaggctccagacaacctggaggc-3 .
PKCδ-GST (glutathione S-transferase) constructs were made using the following oligonucleotides as specific flanking primers for PCR: full-length-PKCδ-GST, 5 -gataatacccgggatggcaccgttcctgcgc-3 (XmaI site) and 5 -ctaagcaggtaccgttccaggaattgctcatatttgg-3 (KpnI site); PKCδ-RD (regulatory domain)-GST, 5 -gataatacccgggatggcaccgttcctgcgc-3 (XmaI site) and 5 -gatataaggtaccgccggttgctcccctcccag-3 (KpnI site); PKCδ-CD-GST, 5 -gatataacccgggatgctcttggctgaggccttgaacc-3 (XmaI site) and 5 -ctaagcaggtaccgttccaggaattgctcatatttgg-3 (KpnI site). The PCR products were digested with XmaI and KpnI restriction enzymes and were cloned into pMT2SM-GST that was similarly digested.
Truncations of the CD of PKCδ were introduced by PCR, using the following oligonucleotides as forward primers: CD 376, 5 -gataatacccgggatgaagtacctgaagaaggacgtggtg-3 (Xma1 site); CD 432, 5 -gataatacccgggatgaaaggccgcttcgaactctacc-3 (Xma1 site); CD 508, 5 -gataatacccgggatggcactcctgactacatcgcccctg-3 (Xma1 site) and CD 616, 5 -gataatacccgggatgccgccctttaagcccaaagtgaaatcc-3 (Xma1 site). The reverse primer was 5 -ctaagcaggtaccgttccaggaattgctcatatttgg-3 (KpnI site).
Construction of GFP-PKCδ-WT, T505A and K376M was described previously [10] GFP-PKCδ A147D was made by sitedirected mutagenesis with PCR using the oligonucleotides, 5 -cggaattcatggcaccgttcctgcgca-3 (EcoRI site) and 5 -gggggtaccctattccaggaattgctcata-3 (KpnI site), as flanking primers and the oligonucleotides, 5 -cccaactatgaaccgccgtggagacattaaacaggccaagattcac-3 and 5 -gtgaatcttggcctgtttaatgtctccacggcggttcatagttggg-3 , as complementary mutagenesis primers.
RNA extraction, RT (reverse transcriptase)-PCR and sub-cloning of VHL mutants expressed in the RCC4 VA cell line
RNA extraction from RCC4 VA cells was performed with the Qiagen RNeasy system according to the manufacturer's instructions. Reverse transcription and PCR was performed using Sigma's SuperScript One-Step RT-PCR with a Platinium Taq System with the primers, C and D. The PCR product was subcloned into pEGFP-N1.
Pull-down and co-immunoprecipitation experiments
Post-transfection (24 h), cells were harvested in 500 µl of lysis buffer [50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 0.5 % NP40 (Nonidet P40) or 0.2 % CHAPS, 20 mM NaF, 2 mM EDTA, 2 mM EGTA, 2 mM orthovanadate and 1 protease inhibitors complete tablet (Roche)]. After 30 min of incubation on ice and centrifugation at 14 000 g for 10 min the supernatants were subjected to immunoprecipitation with a rabbit anti-GFP antibody (0.5 µl per immunoprecipitation) (BD Clontech) and Protein ASepharose, or pull-down with glutathione-Sepharose (15 µl per pull-down) (Amersham) and were incubated for 2 h at 4
• C. The beads were washed five times with 1 ml of lysis buffer and the final bead pellets were resuspended in 40 µl of SB2×, boiled and resolved by SDS/PAGE and Western blotting. Immunoreactivity was analysed by chemiluminescence using the ECL ® system (Amersham).
In vivo polyubiquitination assay
Post-transfection (24 h), HEK-293T cells were pre-treated for 30 min with medium containing 25 µM MG132, and were subsequently stimulated with 400 nM PMA for 30, 60 and 120 min. Finally, cells were lysed in 500 µl of lysis buffer [50 mM Tris/ HCl (pH 7.5), 150 mM NaCl, 1 % NP 40, 20 mM NaF, 2 mM EDTA, 2 mM EGTA, 2 mM orthovanadate, one Complete protease inhibitor tablet (Roche), 10 mM N-ethylmaleimide and
After 30 min of incubation on ice and centrifugation at 14 000 g for 10 min the supernatants were subjected to immunoprecipitation with a mouse anti-HA (haemagglutinin) antibody (3 µg per immunoprecipitation) and Protein A-Sepharose, and were incubated for 2 h at 4
• C. The beads were finally washed five times with lysis buffer and the immunoprecipitated proteins were recovered by adding 40 µl of SB2× to the last bead pellets and by boiling the beads. The proteins were then resolved by SDS/PAGE and Western-blot analysis.
Immunofluorescence and FRET
COS7 cells were transfected with YFP-VHL and PKCδ-GST constructs on coverslips. Post-transfection (24 h) the coverslips were fixed with 2 % PFA (paraformaldehyde) in PBS and after permeabilization and blocking with 0.1 % Triton X-100/1 % BSA in PBS, the coverslips were incubated with the primary rabbit anti-GST antibody (Santa Cruz) (1:250 in PBS/1 % BSA) for 1 h, washed with PBS and incubated for 45 min with a Cy3 (cytidine 3)-conjugated anti-rabbit (1:500) secondary antibody (Dako). Finally, coverslips were mounted on to slides with Mowiol and examined using a confocal laser scanning microscope (LSM 510, Carl Zeiss Inc.) equipped with krypton/argon lasers and with a 1.4 numerical aperture, 63× Plan-APOCHROMAT oil-immersion objective. Double-labelled images (1024 pixels × 1024 pixels) were analysed in sequential scanning mode by exciting YFP at 488 nm and Cy3 at 543 nm. For FRET experiments, COS7 cells were co-transfected with a 3:1 ratio of Myc-empty vector/VHL-WT-GFP or PKCδ-Myc/VHL-WT-GFP. Post-transfection (24 h) the cells were fixed for 10 min with 4 % PFA in PBS. The cells were then permeabilized with 0.2 % Triton X-100 in PBS for 5 min, autofluorescence of the cells was quenched with 1 mg/ml sodium borohydrate in PBS for 5 min and cells were blocked with 1 % BSA in PBS for 5 min. The cells were then subjected to immunofluorescence (1 h) staining with a mouse antiMyc antibody (9E10; CR-UK) previously labelled with Cy3. Then coverslips with cells were mounted with Mowiol containing DABCO (1,4- 
A detailed description of the FRET analysis monitored by FLIM (fluorescence lifetime imaging microscopy) can be found elsewhere [15, 16] . We monitored lifetime in the frequency (phase) domain; phase methods provide an average lifetime whereby sinusoidally modulated light is used to excite the sample. The lag in the emitted fluorescence signal permits measurement of phase (τ p ) and modulation depth (τ m ) of the fluorescence. The lifetime, τ , is the average of phase-shift and relative modulation depth (τm+τp) 2 of the emitted fluorescence signal. All images were taken using a Zeiss Plan-APOCHROMAT 100×, 1.4 numerical aperture, phase 3 oil-immersion objective, with images recorded at a modulation frequency of 80.218 MHz. The donor (pVHL-GFP) was excited using the 488 nm line of an argon/krypton laser and the resultant fluorescence separated using a combination of the dichroic beam splitter (Q 505 LP; Chroma Technology Corp.) and interference filter (HQ510/20; Chroma Technology Corp).
RESULTS AND DISCUSSION
Previous studies have shown, by co-immunoprecipitation, that pVHL interacts with PKCδ [11] . This observation was initially confirmed via co-immunoprecipitation of pVHL-HA from the RCC line, 786-0 VHL, and immunoblotting of endogenous PKCδ (see Supplementary Figure at http://www.BiochemJ.org/bj/397/ bj3970109add.htm) and was extended to determine whether the proteins directly interact in intact cells. Shiao et al. [17] have shown that pVHL localizes to mitochondria in rat clear cell kidney tumours and that altered pVHL leads to malfunction of this organelle. As previously described, the fusion of YFP to the N-terminus of pVHL-WT ( Figure 1A ) leads to its accumulation in structures surrounding the nucleus ( Figure 1B ; pVHL-YFP images, green channel); a similar distribution was observed with a dsRed (red fluorescent protein from the ceral Discosoma sp.)-pVHL construct (results not shown). We have exploited this localization property to determine whether this form of pVHL is able to recruit different PKCδ GST-tagged constructs into these structures. Expression of the full-length, RD or CD of PKCδ in COS7 cells, shows a diffuse cytoplasmic pattern of staining ( Figure 1B, red channel) . However, when co-expressed with YFPpVHL the full-length PKCδ and the CD co-localize with the structures formed by YFP-pVHL ( Figure 1B , top and bottom images). By contrast, the co-expressed RD of PKCδ does not co-localize with pVHL-YFP ( Figure 1B , middle images) demonstrating that the recruitment is specific and not a function of protein co-expression.
Direct pVHL/PKCδ interaction in cells was monitored by FRET, as measured by FLIM. This technique determines the lifetime of the donor (pVHL-GFP) such that when the donor interacts with the acceptor (Myc-PKCδ, immunostained with an anti-Myc antibody previously labelled with the acceptor, Cy3) the lifetime of the donor decreases (see [15, 16] for details of the methods employed in the present study). Figure 1(C) shows the image intensity corresponding to the fluorescence intensity of the donor and the τ map, which corresponds to the lifetime, τ , of the donor (pVHL-GFP). When pVHL-GFP is co-expressed with an Myc-empty vector and co-stained with an anti-Myc-Cy3 antibody, the lifetime of the donor corresponds to the lifetime of the GFP. However when co-expressed with Myc-PKCδ the observed lifetime decreases significantly, demonstrating the existence of FRET between the donor and the anti-Myc-Cy3 acceptor. In Figure 1(D) the cumulative lifetimes of all pixels recorded for the pVHL-GFP/Myc-empty vector and pVHL-GFP/Myc-PKCδ are presented. This two-dimensional histogram shows the lifetimes measured by the two parameters assessed by FLIM (phase and modulation); the concomitant decrease in both indicates a significant decrease in GFP lifetime of the donor due to FRET. This acceptor-dependent lifetime decrease indicates a close interaction between pVHL and PKCδ in the cytoplasm of intact cells.
To determine the domain of interaction of these two proteins, several deletion constructs were employed (Figure 2 ). We found that for PKCδ, the full-length protein and the CD interact strongly with pVHL-GFP ( Figure 2B ). Similar results were obtained with a T7-pVHL construct, indicating that neither the tag nor the position influence this behaviour (results not shown). To more precisely dissect out the interaction of PKCδ and pVHL, we further truncated the PKCδ CD ( Figure 2C ). GST pull-down experiments (as illustrated in Figure 2D ) revealed that truncation mutants 376 CD-GST and 432 CD-GST still interact with pVHL; the mutants with shorter truncations of the PKCδ CD, 508 CD-GST and 616 CD-GST, do not pull-down pVHL. Although the expression level of the 508 truncation mutant is low in this experiment, this was not a consistent observation and at equivalent levels of expression with the 376 or 432 truncation mutants there was still no equivalent ability to interact with pVHL. In summary, these results suggest that the domain of interaction of PKCδ with pVHL includes residues between positions 432 and 508.
Figure 3 pVHL interaction with PKCδ mutants
HEK-293T cells stably expressing pVHL-WT-T7 were co-transfected with WT PKCδ, and PKCδ mutants (A147D, K376M and T505A). Cells co-transfected with WT PKCδ were treated with or without 400 nM PMA for 24 h. After 48 h of transfection the cells were lysed and subjected to immunoprecipitation (IP) with a rabbit anti-GFP antibody and protein complexes were resolved by SDS/PAGE and immunoblot (IB) analysis.
As the domain of interaction overlaps the catalytic site of PKCδ and includes the activation loop, we investigated whether proteins with mutations of the catalytic lysine (K376M) or of the activation-loop phosphorylation site T505A were able to interact with pVHL. We also determined the effect of chronic PMA treatment (24 h) on the interaction between WT PKCδ and pVHL, as well as in the interaction between the constitutively active PKCδ mutant (A147D) and pVHL. These studies showed that a modest increase in pVHL recovery was observed upon PMA treatment; however, none of the mutations significantly affected the interaction of PKCδ with pVHL ( Figure 3 ). This indicates that, although the CD is sufficient, PKCδ activity itself is not required for the pVHL interaction.
For comparison of the mode of interaction of PKCδ and Hif1α with regard to pVHL, a series of deletion/mutation pVHL constructs ( Figure 4A ) was tested for interaction with PKCδ; these included deletions of the Hif1α-interacting domain (residues 113-122) and mutations that prevent interaction with the elongin complex (C162W and R167W). Pull-down experiments ( Figures 4B and 4D) revealed that PKCδ binds the 1-122 truncation mutant but not the 1-113 truncation mutant, suggesting that the domain of interaction between pVHL and PKCδ includes residues between positions 113 and 122, as previously reported for the regulatory domain of aPKC [18] . However, the pVHL 87-130 deletion mutant interacts with PKCδ 376 CD-GST, revealing the existence of an additional point of contact. Interestingly, the three hot-spot mutations for human VHL syndromes, Y98H, C162W and R167W, all interact with PKCδ ( Figure 4B ). This indicates that mutations which affect the Hif1α interaction (as opposed to the elongin C interaction, in particular 87-130 and Y98H), may retain their 'activity' towards PKCδ.
To further characterize the mode of interaction of pVHL with PKCδ, we have isolated the VHL cDNA sequences from RCC4 lines lacking pVHL activity against Hif1α (RCC4 VA). We have thus demonstrated that two mutant alleles are present, namely S65W and S65W/ 114-154 ( Figure 4C ). These were sub-cloned into the pEGFP-N1 expression vector and used to determine their ability to bind PKCδ by GST pull-down experiments ( Figure 4D ). The pVHL S65W mutant interacted with PKCδ, whereas the pVHL S65W/ 114-154 mutant, corresponding to the deletion of exon 2, lost its ability to bind PKCδ. This result alongside the 87-130 deletion data, indicates that the second domain of interaction between PKCδ and pVHL is likely to be located between residues 130 and 154. These results also show that the two domains of interaction (residues 113-122 and 130-154) can act independently. The combination of these two domains may increase the stability of the complex or have functional activity. Indeed, as noted by Datta et al. [13] the pVHL sequence comprising residues 113-122 contains a pseudo-substrate-like sequence that has the ability to inhibit the kinase activity of PKCδ in vitro.
To determine whether the expression level of PKCδ is influenced by pVHL activity, we initially determined the steadystate levels of different PKCs expressed in RCC4 VA or in the same cells re-expressing WT pVHL (RCC4 VHL). Since Lee et al. [19] have shown that pVHL shuttles between the cytoplasm and nucleus during the cell-cycle (being predominantly nuclear in sparsely growing cells and cytosolic in confluent cells) and because the interaction between pVHL and PKCδ occurs in the cytoplasm, we have analysed PKC's expression level under different culture conditions. Thus RCC4 lines were seeded sparsely (20 % confluent) or at high density (100 %). Amongst the PKCs tested, only PKCδ showed a significantly decreased expression level in RCC4 VHL versus RCC4 VA cells; this was only observed when cells were grown at high density ( Figure 5A ). PKCε, which, like PKCδ, belongs to the novel PKC family, showed the opposite expression profile, without any effect from cell density ( Figure 5A ). Contrary to expectation, PKCι and PKCζ , which have been shown to be polyubiquitinated by pVHL, were modestly up-regulated when WT pVHL is expressed and cells were cultivated at high density ( Figure 5A ; as described below). As previously shown, Hif1α expression levels were increased when pVHL activity was lost ( Figure 5A ). Since Pause et al. [20] have shown that the lack of VHL activity only affects cell-cycle arrest upon serum withdrawal and that cell-cycle exit by contact inhibition remains identical in RCC4 and RCC4 lines that reexpress VHL, we can indeed conclude that the effects observed at high density are not a function of a differential ability of these cells to arrest the cell-cycle. This decrease in PKCδ expression level only in high density RCC4 VA cells suggests that pVHL could promote the down-regulation of PKCδ expression under these conditions and that the presence of pVHL in the cytoplasm is necessary for this degradation. It is of note that no modification of the steady-state phosphorylation of PKCδ at Ser 643 and Thr 505 was observed in RCC4 VA and RCC4 VHL cells at different cell densities ( Figure 5B ). PMA-induced degradation was also followed in high-density RCC4 VA and RCC4 VHL cells, and by monitoring PKCα, PKCδ and PKCε levels with Western-blot analysis ( Figure 6A ). PMA treatment of RCC4 cell lines induced down-regulation of all three PKC isoforms, with almost complete loss occurring after 24 h of treatment. The involvement of the proteasome in this PMA-induced response was indicated by its inhibition upon cotreatment with MG132. The values obtained by densitometric analysis of different sets of experiments (n = 6 for PKCδ, and n = 5 for PKCα and PKCε) and logarithmic expression of these time courses have been used to determine the rates of degradation (slope of the curves) of PKCs in RCC4 cell lines ( Figure 6B HA-tagged ubiquitin in HEK-293T cells confirmed the ubiquitinligase activity of pVHL towards PKCδ under overexpression conditions ( Figure 6D) .
We have shown previously that the down-regulation of PKCδ expression during cell-cycle progression is dependent on the phosphorylation of the activation loop at Thr 505 and can be promoted by calyculin A, a PP2A (protein phosphatase 2A) selective inhibitor, and inhibited by the PKC inhibitor BIM-1 [10] . This pattern of behaviour is only partially retained in the RCC4 lines ( Figure 6C ). Co-treatment of RCC4 lines with calyculin A does not inhibit PKCδ degradation, whereas inhibition of PKCδ with BIM-1 or rotterlin, but not the more PKCα-selective, Gö 6976, blocks PMA-induced degradation of PKCδ in both cell lines. It should be noted that Gö 6976 was effective in blocking PMAinduced PKCα degradation. The results indicate that, although the presence of WT pVHL is associated with increased PMAinduced degradation of PKCδ, the degradation of PKCδ in these RCCs requires functional kinase activity, clearly contrasting with the requirement for pVHL-PKCδ interaction (as described above).
The distinction between PMA-induced PKCδ down-regulation and the PKCδ/pVHL interaction raised the question as to whether the effects observed either in RCC4 or RCC4 VHL cells are due to clonal variation or reflect an independent function for the interaction. Since direct siRNA (small interfering RNA) knockdown of pVHL expression in the RCC4 lines has not been possible (results not shown), we investigated this issue by analysis of two other RCC lines that retain or lack pVHL activity. Specifically the UMRC2 (VA and VHL) and the 786 O (VA and VHL) lines were employed to determine the steady-state PKCδ level and also its degradation behaviour in these cell lines (Figure 7) . UMRC2 VA has weak expression of a mutated form of pVHL, whereas the 786 O VA cell line lacks detectable pVHL expression. In contrast with the results obtained using the RCC4 lines, the presence of pVHL in UMRC2 or 786 O cell lines does not change the steady-state level of PKCδ (the concentration being assessed as a function of tubulin expression). In comparison with the steady-state behaviour of aPKCs, we noted that the effect of pVHL expression does not correlate with the overall level of protein, but rather with the relative accumulation of the dephosphorylated form of the protein. The low abundance of the shifted phosphorylated aPKC form makes it impossible to determine whether the loss of this more slowly migrating phosphorylated form is directly related to the increase of the faster migrating form or not, i.e. whether the apparent effect of pVHL is due to degradation of the phosphorylated form as proposed elsewhere [21] or dephosphorylation of the pVHL-associated kinase.
For PMA-induced degradation of PKCδ, this is significantly increased in UMRC2 VA cells by comparison with the UMRC2 VHL; there is a modest and equivalent extent of PMA-induced degradation in the 786 O VA and VHL cells ( Figure 7B ). These results demonstrate that there is no correlation between the presence of active pVHL and the induced degradation of PKCδ in these RCC lines. It is evident that pVHL is not required for the activation-induced down-regulation of PKCδ and that the differences in PKCδ degradation observed between these RCC lines are most likely due to clonal variation. Similarly a comparison of the levels of PKCδ in the three pairs of RCC lines indicated that there is also no correlation between PKCδ steady-state levels and VHL expression.
The lack of a requirement for pVHL in the PMA-induced downregulation and steady-state turnover of PKCδ juxtaposed with the clear demonstration of complex-formation in cells, supports the notion that through this interaction pVHL influences PKCδ activity. Two different studies have indeed reported such functions. Pal et al. [11] have demonstrated that pVHL can block translocation of PKCζ and PKCδ to cell membranes, blocking activation and preventing a signalling step that leads to VPF/VEGF expression. Datta et al. [13] have shown that PKCδ kinase activity in vitro can be inhibited by pVHL-derived peptides and that in the context of IGF-I signalling, pVHL can inhibit the association of PKCδ with IGF-IR, decreasing the invasiveness of the cells expressing pVHL. These effects of complex-formation on PKCδ function/activity indicate that the key role of the interaction is in tempering the immediate functional output of PKCδ rather than the more characteristic function of pVHL i.e., the induced degradation of the pVHL-associated protein. To assess whether this is due to a direct effect on PKCδ activity effected through the defined in vitro inhibitory effect of pVHL [13] , we monitored PKCδ activity in intact cells by employing a novel autophosphorylation site (J. Durgan and P. J. Parker, unpublished work). PMA-induced phosphorylation of PKCδ at Ser 299 was not significantly affected by the presence or absence of pVHL (Figure 8 ). The lack of an effect of pVHL on PKCδ activity juxtaposed with its lack of involvement in the PKCδ down-regulation pathway indicates that its functional effect is likely to be directed at a specific substrate(s), perhaps mediated through localization.
PKCδ has been implicated in cell-cycle regulation and apoptosis in many different cell types. The extent to which these properties contribute to the pattern of pVHL-associated disease progression remains to be determined. However, it is now clear that this will not be reflected simply in the altered turnover of PKCδ, nor through direct inhibition, but rather through altered localization and/or selective substrate targeting. This distinction is important, as it determines the nature of the parameters required for an assessment of whether PKCδ contributes to VHL disease sub-classes in the clinical setting.
